Charts are never wrong, analysis is!
Charts are never wrong, analysis is!

Charts are never wrong, analysis is!

DSIJ Intelligence-3 Article rating: 4.4

Scaling is an issue that is often overlooked in technical community, but since it can have an important influence on how trendlines can be interpreted, it should not be ignored at any cost. The difference between a logarithmic price chart and a linear price chart can be very slight when one is analysing a chart in the short-term, where price fluctuations are relatively small.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 3.9

The market opened in green on January 25, 2021, overall volumes in futures & options currently stand at 3,42,07,296 contracts with a turnover of Rs. 31,26,119.13 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 4.1

The market opened in green on January 25, 2021, overall volumes in futures & options currently stand at 3,42,07,296 contracts with a turnover of Rs. 31,26,119.13 crore.

Caplin Point falls despite getting USFDA approval for Argatroban injection
Caplin Point falls despite getting USFDA approval for Argatroban injection

Caplin Point falls despite getting USFDA approval for Argatroban injection

DSIJ Intelligence Article rating: 3.0

The subsidiary company of Caplin Point Laboratories Ltd namely, Caplin Steriles Limited informed that it has received final approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Argatroban injection, 50 mg/50 ml (1 mg/ml) single-dose vial presentation.

Nifty: Formation of a top or a mere pullback?
Nifty: Formation of a top or a mere pullback?

Nifty: Formation of a top or a mere pullback?

DSIJ Intelligence-3 Article rating: 4.6

It’s said that markets give us hints well in advance of what is going to happen in the coming days. So, here are a few interesting observations witnessed in the markets last week, which is signalling that something big is going to happen as these observations are aligned with a host of events, which are lined up in the coming weeks.

Alembic gets USFDA nod for Midodrine Hydrochloride Tablets
Alembic gets USFDA nod for Midodrine Hydrochloride Tablets

Alembic gets USFDA nod for Midodrine Hydrochloride Tablets

DSIJ Intelligence Article rating: 4.7

Drug manufacturer, Alembic Pharmaceuticals informed the exchanges on Friday that it had secured approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. 

RSS
First25952596259725982600260226032604Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR